Osivax raises USD 9 M to boost its universal flu vaccine approach
France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the clinical development of its lead flu vaccine, back up strategic corporate growth and evaluate a second-generation vaccine candidate to target both A- and B- strains of influenza. At present, the unmet needs in the Influenza therapy market are the limitation of flu vaccines in targeting all the regions of viruses. Whereas, Osivax has come up with a universal fl...
